Novo Nordisk Pharmatech showing insulin boost to CHO cell productivity at PepTalk San Diego


Novo Nordisk Pharmatech showing insulin boost to CHO cell productivity at PepTalk San Diego


NovoNordics 150x58

News | Novo Nordisk Pharmatech A/S

DECEMBER 19, 2017

Koege, Denmark: – Novo Nordisk Pharmatech A/S, the leading worldwide supplier of high-quality ingredients for the biopharmaceutical, pharmaceutical and personal care industries, will use the 2018 PepTalk Protein Science Week conference in San Diego to highlight the advances it has achieved in using recombinant human insulin to boost cell growth and density.

Novo Nordisk will once again be an exhibitor at the event with a stand at Booth 507 at the Hilton Bayfront Hotel. The Novo Nordisk team led by Product Manager Magnus Franzmann will be highlighting the roles that the company’s recombinant insulin can play in innovative biologics and production of pharmaceutical grade quaternary ammonium compounds (‘quats’).

Increased cell growth and density

“We believe professionals working in R&D or product development in cell culture will be highly interested in the advances we have been able to achieve in cell growth, productivity and cell density,” commented Novo Nordisk Pharmatech Product Manager, Magnus Franzmann.

“We will be able to show researchers in cell culture and vaccine development at PepTalk that adding animal origin-free insulin to three leading commercially available off-the-shelf chemically defined media resulted in significant increases in viable cell density. In addition, insulin has been proven to aid in the expression of difficult to express proteins.,’ said Mr. Franzmann.

“Our products are manufactured to cGMP standards to guarantee global regulatory compliance and consistent high quality. We can also assure extensive regulatory documentation, continuous availability across a secure global supply chain, high levels of service and support,” said Mr. Franzmann.

N1

CHO cell productivity

Novo Nordisk Pharmatech researchers, in collaboration with UAB, have been able to increase viable Chinese hamster ovary (CHO) epithelial cell density by adding non-animal insulin to the chemically defined media that have now become the gold standard for safe and reliable production.

CHO cells are one of the most widely used platforms for the production of biopharmaceuticals. Increased demand for safety and reliability has moved the standard for CHO cell culture media from Serum-containing to Serum-free and further on to chemically defined media.

Win a Fire tablet

“Supplementing three leading commercially available chemically defined media with animal origin-free insulin has resulted in significant increases in viable cell density,” said Mr. Franzmann.

“In addition, insulin has been proven to aid in the expression of difficult to express proteins,” he added.

“We will be delighted to explain the powerful roles that our insulins can play in upstream processes to our visitors at PepTalk, who will also have the chance to win an Amazon Fire 7″ tablet on our stand,” said Mr. Franzmann.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, and now part of the Novo Nordisk pharmaceutical group since its acquisition in 1986. On September1, 2015, the company became Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2016, Novo Nordisk Pharmatech reported world sales totaling 669 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About PepTalk 2018

The annual Protein Science Week, PepTalk, is one of the world’s foremost forums for protein science researchers. Now In its 16th year, PepTalk attracts nearly 1,300 experts from academia, biotech and pharma organizations in more than 40 countries. A co-located exhibition features more than 100 companies.

PepTalk 2018 is a five-day event, opening January 9 at the Hilton Bayfront Hotel in San Diego, CA.

This event will cover a wide spectrum, from upstream protein R&D science to downstream biologics. The conference programs feature keynote presentations, case studies and new unpublished data from thought leaders in academia and industry. PepTalk also features three-hour short courses focusing on topics such as Production Challenges for ADCs and Fusion Proteins, Biologics Formulation Development and NextGen Sequencing of Antibody Libraries:

PepTalk 2016 will also feature extended Training Seminars and Student Fellowships providing young researchers an opportunity to present their latest work.

The event is organized by Cambridge Healthtech Institute with more information at:
www.chi-peptalk.com

Media Contact

Vanessa León, Marketing Manager, Novo Nordisk Pharmatech A/S
Tel:+45 404 262 84
Email: vnlt@novonordiskpharmatech.com

Resources

Click on Novo Nordisk Pharmatech at PepTalk San Diego 2018 for more information.
Click on Novo Nordisk Pharmatech to contact the company directly.
Click on Recombinant human insulin for further information.


Supplier Information
Supplier: Novo Nordisk Pharmatech A/S
Address: Koebenhavnsvej 216, 4600 Koege, Denmark
Tel: +45 566 71000
Fax: + 33 38 331 2483
Website: http://novonordiskpharmatech.com/


Comments are closed.